Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F20%3A10427560" target="_blank" >RIV/00179906:_____/20:10427560 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/20:00074013
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=i4yj0TYJYA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=i4yj0TYJYA</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HS9.0000000000000485" target="_blank" >10.1097/HS9.0000000000000485</a>

Result language
angličtina
Original language name
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
Original language description
Interferon alpha (IFNa) and hydroxyurea (HU) are recommended for cytoreductive treatment of polycythaemia vera (PV),1 a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by deregulated hematopoiesis driven by mutated constitutive-active JAK2. In addition to its ability to induce hematologic responses, IFNa has disease-modifying properties as shown by the high rate of reduction of the mutant JAK2V617F allele burden. In elderly patients with PV, however, a higher number of toxicity-related dose reductions or discontinuations and lower hematological response rates have been reported among IFNa-treated patients compared to HU.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)